About Magen BioSciences
Magen BioSciences is a Healthcare company based in Waltham (United States) founded in 2006, and was acquired by PPD in April 2009. Novel pharmaceuticals for skin diseases are developed. Magen BioSciences has raised $17.2 million across 2 funding rounds from investors including ARE, PPD and Arch Venture Partners. Its chief executive, as recorded, is Brian Gallagher. Its focus areas include Life Sciences, Dermatology, Drugs and Aesthetics. Its competitors include Revance Therapeutics, Castle Creek Pharma and Dermavant; 3 of its 3 listed competitors have raised funding.
Company details
Magen BioSciences was established in 2006 in Waltham, United States, within the biotechnology sector. Novel pharmaceutical products are identified and developed by the company to address skin health and appearance. A science-based method is employed, drawing on knowledge of the biology in normal and diseased skin conditions. Operations center on pharmaceutical innovation targeted at dermatological applications.
- Headquarters Waltham, United States
- Stage Acquired
- SectorsHealthcare
- Website magenbiosciences.com
- Social LinkedIn
- Acquired by PPD (Apr 2009)
Funding Insights of Magen BioSciences
Magen BioSciences has successfully raised a total of $17.2M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $15.4 million completed in April 2006. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $17.2M
- Total Rounds 2
- Last Round Series A — $15.4M
- First Round $1.8M
(Mar 2006)
- Investors Count 9
All 2 funding rounds of Magen BioSciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2006 | $15.4M | Series A | – | Highland Capital Partners | |
| Mar 2006 | $1.8M | Seed | – | – | – |
10 investors in total: 10 institutional.
Investors in Magen BioSciences
Magen BioSciences has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE, PPD and Arch Venture Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investment and entrepreneur support services. | hcp.com | |||
Early-stage tech startups are funded by Flybridge Capital Partners. | flybridge.com | New York, United States | ||
Investment management in biotech, technology, energy, shipping, financials, and litigation sectors. | 2003 | qvt.com | ||
Venture capital firm focused on life science companies | 1986 | archventure.com | Chicago, United States | |
Seed and early-stage technology companies are funded by Lux Capital. | luxcapital.com | Menlo Park, United States | ||
Capital is invested in life science innovations for healthcare transformation. | tvm-capital.com | Munich, Germany | ||
Venture capital firm focused on tech sectors | venrock.com | Palo Alto, United States | ||
Venture capital firm | idgcapital.com | New York, United States | ||
REIT that invests in campuses, multi-tenant spaces and build-to-suit facilities in the US | 1994 | are.com | Pasadena, United States | |
CRO providing diversified clinical development services | 1985 | ppd.com | Wilmington, United States |
Investor details for Magen BioSciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Magen BioSciences
1 people are tracked at Magen BioSciences (1 in leadership).
| Name | Role | Group |
|---|---|---|
Brian Gallagher | CEO | Leadership |
Complete people profiles for Magen BioSciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Magen BioSciences
4 dated milestones of Magen BioSciences across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Magen BioSciences is founded.
- Funding First funding round of $1.8M.
- Funding Latest funding round, Series A, of $15.4M.
- Exit Acquired by PPD.
Competitors of Magen BioSciences
Magen BioSciences has 3 listed competitors in our database, 3 of them funded. They include Revance Therapeutics, Castle Creek Pharma and Dermavant.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| revance.com | 2002 | Newark, United States | $154.56M | 597 | Neurotoxin products for aesthetic and therapeutic skin treatments are developed. | |
| castlecreekpharma.com | 2015 | Basking Ridge, United States | $663.15M | 72 | Drugs for skin diseases, ENT disorders, and rare diseases such as urea cycle disorders | |
| dermavant.com | 2016 | Phoenix, United States | $160M | Small molecule therapeutics for inflammatory skin diseases are developed. |
Detailed competitors of Magen BioSciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Dermatology
3 companies that operate in the same segment as Magen BioSciences (Dermatology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Neurotoxin products for aesthetic and therapeutic skin treatments are developed. | 2002 | Newark, New Jersey, United States | USD 154.56 M | USD 234.04 M | 597 | |
Diagnostic tests for cancer prognosis are provided. | 2008 | Friendswood, Texas, United States | USD 61.97 M | USD 344.23 M | 761 | |
Adhesive patch biopsies for skin cancer detection are provided. | 1996 | San Diego, California, United States | USD 24.37 M | USD 15.3 M | 259 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Magen Biosciences
Complete news archive for Magen BioSciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Magen BioSciences
Magen BioSciences was founded in 2006.
Magen BioSciences is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
Brian Gallagher is the CEO of Magen BioSciences, as recorded in our data.
Magen BioSciences is a funded company, having raised a total of $17.2M across 2 funding rounds to date. The company's 1st funding round was a Seed of $1.8M, raised on Mar 2006.
Magen BioSciences was established in 2006 in Waltham, United States, within the biotechnology sector. Novel pharmaceutical products are identified and developed by the company to address skin health and appearance. A science-based method is employed, drawing on knowledge of the biology in normal and diseased skin conditions. Operations center on pharmaceutical innovation targeted at dermatological applications.
Magen BioSciences's top competitors include Revance Therapeutics, Dermavant and Castle Creek Pharma.
Magen BioSciences has 10 investors. Key investors include ARE, PPD, Arch Venture Partners, Highland Capital Partners, and Flybridge Capital Partners.
Yes. Magen BioSciences was acquired by PPD in April 2009.